| Literature DB >> 31201181 |
Ryan C Gimple1,2, Reilly L Kidwell1, Leo J Y Kim1,2, Tengqian Sun3, Anthony D Gromovsky4, Qiulian Wu1, Megan Wolf5, Deguan Lv1, Shruti Bhargava1, Li Jiang1, Briana C Prager1,2,6, Xiuxing Wang1, Qing Ye3, Zhe Zhu1, Guoxin Zhang1, Zhen Dong1, Linjie Zhao1, Derrick Lee1, Junfeng Bi7, Andrew E Sloan8,9, Paul S Mischel7,10,11, J Mark Brown4, Hu Cang3, Tao Huan5, Stephen C Mack12,13, Qi Xie14,15, Jeremy N Rich14,11,16.
Abstract
Glioblastoma ranks among the most aggressive and lethal of all human cancers. Functionally defined glioma stem cells (GSC) contribute to this poor prognosis by driving therapeutic resistance and maintaining cellular heterogeneity. To understand the molecular processes essential for GSC maintenance and tumorigenicity, we interrogated the superenhancer landscapes of primary glioblastoma specimens and in vitro GSCs. GSCs epigenetically upregulated ELOVL2, a key polyunsaturated fatty-acid synthesis enzyme. Targeting ELOVL2 inhibited glioblastoma cell growth and tumor initiation. ELOVL2 depletion altered cellular membrane phospholipid composition, disrupted membrane structural properties, and diminished EGFR signaling through control of fatty-acid elongation. In support of the translational potential of these findings, dual targeting of polyunsaturated fatty-acid synthesis and EGFR signaling had a combinatorial cytotoxic effect on GSCs. SIGNIFICANCE: Glioblastoma remains a devastating disease despite extensive characterization. We profiled epigenomic landscapes of glioblastoma to pinpoint cell state-specific dependencies and therapeutic vulnerabilities. GSCs utilize polyunsaturated fatty-acid synthesis to support membrane architecture, inhibition of which impairs EGFR signaling and GSC proliferation. Combinatorial targeting of these networks represents a promising therapeutic strategy.See related commentary by Affronti and Wellen, p. 1161.This article is highlighted in the In This Issue feature, p. 1143. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31201181 PMCID: PMC6785242 DOI: 10.1158/2159-8290.CD-19-0061
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397